Impaired development of neocortical circuits contributes to the neurological

alterations in DYRK1A haploinsufficiency syndrome by Arranz, Juan et al.
	 1 
Impaired development of neocortical circuits contributes to the neurological 
alterations in DYRK1A haploinsufficiency syndrome 
 
Juan Arranza,b,#, Elisa Balduccia,b,#, Krisztina Aratób,c,#, Gentzane Sánchez-
Elexpurub,d,1, Sònia Najasa,2, Alberto Parrase, Elena Rebolloa, Isabel Pijuana,b, Ionas 
Erbc, Gaetano Verdec,3, Ignasi Sahunf, Maria J. Barallobrea,b, José J. Lucase,g, Marina 
P. Sánchezb,d, Susana de la Lunab,c,h,i,*, Maria L. Arbonésa,b,* 
 
aInstituto de Biología Molecular de Barcelona (IBMB), CSIC, 08028-Barcelona, 
Spain. 
bCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 
Barcelona, Spain. 
cCentre for Genomic Regulation (CRG), The Barcelona Institute for Science and 
Technology (BIST), 08003-Barcelona, Spain. 
dDepartment of Neuroscience, Laboratory of Neurology, IIS-Jiménez Díaz 
Foundation, 28040-Madrid, Spain. 
eDepartment of Molecular Neuropathology, Centro de Biología Molecular Severo 
Ochoa (CBMSO), CSIC/UAM, 28049-Madrid, Spain. 
fPCB-PRBB Animal Facility Alliance, 08020-Barcelona, Spain. 
gCentro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas 
(CIBERNED), Madrid, Spain. 
hUniversitat Pompeu Fabra (UPF), 08003-Barcelona, Spain. 
iInstitució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. 
 
*Co-corresponding authors: M. L. Arbonés, IBMB, Barcelona Scientific Parc, Baldiri 
Reixac 4-8, 08028-Barcelona, Spain. Tel: +34 934033728; Fax: +34 934034979; 
Email: marbmc@ibmb.csic.es, and S. de la Luna, CRG, Dr Aiguader 88, 08003-
Barcelona, Spain. Tel: +34 933160144; Fax: +34 933160099; Email: 
susana.luna@crg.eu 
 
#These authors contributed equally to the work. *co-senior authors. 
 
1Present address is: Cambridge Institute for medical Research, University of 
Cambridge, Cambridge, UK. 
2Present address is: Max Planck Institute of Biochemistry, Munich, Germany. 
3Present address is: Faculty of Medicine and Health Sciences, Universitat 
Internacional de Catalunya, Barcelona, Spain.  
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/438861doi: bioRxiv preprint first posted online Oct. 10, 2018; 
	 2 
ABSTRACT 
Autism spectrum disorders are early onset neurodevelopmental disorders 
characterized by deficits in social communication and restricted repetitive behaviors, 
yet they are quite heterogeneous in terms of their genetic basis and phenotypic 
manifestations. Recently, de novo pathogenic mutations in DYRK1A, a chromosome 
21 gene associated to neuropathological traits of Down syndrome, have been 
identified in patients presenting a recognizable syndrome included in the autism 
spectrum. These mutations produce DYRK1A kinases with partial or complete 
absence of the catalytic domain, or they represent missense mutations located within 
this domain. Here, we undertook an extensive biochemical characterization of the 
DYRK1A missense mutations reported to date and show that most of them, but not 
all, result in enzymatically dead DYRK1A proteins. We also show that 
haploinsufficient Dyrk1a+/- mutant mice mirror the neurological traits associated with 
the human pathology, such as defective social interactions, stereotypic behaviors 
and epileptic activity. These mutant mice present altered proportions of excitatory 
and inhibitory neocortical neurons and synapses. Moreover, we provide evidence 
that alterations in the production of cortical excitatory neurons are contributing to 
these defects. Indeed, by the end of the neurogenic period, the expression of 
developmental regulated genes involved in neuron differentiation and/or activity is 
altered. Therefore, our data indicate that altered neocortical neurogenesis could 
critically affect the formation of cortical circuits, thereby contributing to the 
neuropathological changes in DYRK1A haploinsufficiency syndrome. 
 
Keywords: autism spectrum disorder, cerebral cortex, DYRK1A mutations, epilepsy, 
neurodevelopment, transcriptome. 
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1. Introduction 
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by 
social communication deficits and restricted repetitive behaviors (Lord and Bishop, 
2015), and it is frequent associated with intellectual disability (ID), language deficits 
and seizures (Geschwind, 2009; Sztainberg and Zoghbi, 2016). The causes of ASD 
remain largely unknown, although a genetic cause has been identified in around 25% 
of cases (Huguet et al., 2013). These genetic alterations include chromosomal 
rearrangements, de novo copy-number variants and de novo mutations in the 
coding-sequence of genes associated with chromatin remodeling, mRNA translation 
or synaptic function (de la Torre-Ubieta et al., 2016). Additionally, alterations in the 
production or migration of neocortical neurons are a point of convergence for ASD 
and ID (de la Torre-Ubieta et al., 2016; Ernst, 2016; Packer, 2016). 
DYRK1A is a member of the conserved dual-specificity tyrosine-regulated 
kinase (DYRK) family of protein kinases (Aranda et al., 2011) that has different 
functions in the nervous system (Tejedor and Hammerle, 2011). This kinase 
influences brain growth, an activity that is conserved across evolution (Fotaki et al., 
2002; Kim et al., 2017; Tejedor et al., 1995). DYRK1A is located within the Down 
syndrome (DS) critical region on human chromosome 21 (Guimera et al., 1996). 
There is evidence that triplication of the gene contributes to neurogenic cortical 
defects (Najas et al., 2015) and other neurological deficits in DS, making it a potential 
drug target for DS-associated neuropathologies (Becker et al., 2014). Recently, 
mutations in DYRK1A have been identified in a recognizable syndromic disorder 
(DYRK1A haploinsufficiency syndrome [DHS], also known as DYRK1A-related 
intellectual disability syndrome; ORPHANET:464306; OMIM:614104). ASD-related 
deficits are common clinical manifestations in DHS, which include moderate to 
severe ID, intrauterine growth retardation, developmental delay, microcephaly, 
seizures, speech problems, motor gait disturbances and a dysmorphic facies (Earl et 
al., 2017; Luco et al., 2016; van Bon et al., 2016). The mutations identified to date in 
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patients with DHS are de novo, involving chromosomal rearrangements (Courcet et 
al., 2012; Moller et al., 2008; van Bon et al., 2011), small insertions or deletions, and 
nonsense mutations (Courcet et al., 2012; Earl et al., 2017; O'Roak et al., 2012; van 
Bon et al., 2016 and references therein). These mutations lead to the production of 
truncated DYRK1A proteins that lack partially o totally the kinase domain and that 
are therefore catalytically inactive. DYRK1A missense mutations have also been 
identified in patients with a distinctive DHS phenotype (Bronicki et al., 2015; Dang et 
al., 2018; De Rubeis et al., 2014; Deciphering Developmental Disorders, 2015; Evers 
et al., 2017; Ji et al., 2015; Ruaud et al., 2015; Stessman et al., 2017; Trujillano et 
al., 2017; Wang et al., 2016; Zhang et al., 2015). The structural modeling of these 
mutations predicts that they are loss-of-function (LoF) mutations (Evers et al., 2017; 
Ji et al., 2015). However, experimental data supporting this prediction have been 
reported only for a few of them (Dang et al., 2018; Widowati et al., 2018). 
The Dyrk1a+/- mouse displays some of the core traits of DHS, including 
developmental delay, microcephaly, gait disturbances and learning problems (Arque 
et al., 2008; Fotaki et al., 2002; Fotaki et al., 2004). The cell density in the neocortex 
of the adult mutant mouse is altered (Fotaki et al., 2002; Guedj et al., 2012) but the 
origin of this alteration and the neuronal components affected are unknown. To gain 
additional insight into the pathogenesis of DHS, we have performed a biochemical 
study to assess the impact of all reported missense mutations within the catalytic 
domain on DYRK1A activity. Furthermore, we analyzed the cytoarchitecture and 
gene expression profile of the neocortex in Dyrk1a+/- mice, also performing 
behavioral tests and obtaining electroencephalogram (EEG) recordings from these 
animals. Our results indicate that defects in the production of excitatory neocortical 
neurons are critical to the neuropathology of DHS. 
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2. Materials and methods 
2.1. Plasmids 
The plasmids to express HA-tagged DYRK1A have been described previously 
(Alvarez et al., 2003: human isoform 754 aa; NP_569120), both the wild type (WT) or 
a kinase inactive version in which the ATP binding lysine 179 (K188R in the 763 aa 
isoform) was replaced by arginine. Single nucleotide mutations (numbering based on 
the 763 aa isoform, as appears in most publications: Supplementary Table 1 and Fig. 
1A) were introduced into the HA-DYRK1A expression plasmid using the 
QuickChange Multi Site-Directed Mutagenesis Kit, according to the manufacturer’s 
instructions (Agilent Technologies) and with primers specific to each mutant 
(Supplementary Table 2). The A469fs* and A489fs* mutations were produced by a T 
or C deletion, respectively, and the same alterations were created in the DYRK1A 
expression plasmid. The plasmids generated by site-directed mutagenesis were 
verified by DNA sequencing and the transfection efficiency was assessed by co-
transfection with a green fluorescent protein (GFP) expression plasmid (pEGFP-C1, 
Clontech). 
 
2.2. Animals 
We used embryos and postnatal and adult Dyrk1a+/- mice and their control Dyrk1a+/+ 
littermates, generated and genotyped as described elsewhere (Fotaki et al., 2002; 
Najas et al., 2015). The day of the vaginal plug was defined as E0 and the day of 
birth was defined as P0. After weaning, mice from the same litter and of the same 
gender were housed in groups. The animals were maintained at the PCB-PRBB 
Animal Facility in ventilated cages on a 12 h light/dark cycle, at approximately 20°C 
and in 60% humidity, and with food and water supplied ad libitum. For 
bromodeoxyuridine (BrdU) birthdating experiments, pregnant females were 
peritoneally injected with a BrdU solution (50 mg/kg; Sigma), two injections spaced 4 
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h, and pups were collected and processed at P7. Experimental procedures were 
carried out in accordance with the European Union guidelines (Directive 2010/63/EU) 
and the protocols were approved by the Ethics Committee of the CSIC, PCB-PRBB, 
CBM and Fundación Jiménez Díaz. 
 
2.3. Cell culture and transfection 
The HEK293T cell line was obtained from the American Type Culture Collection 
(www.atcc.org) and used for the exogenous expression of DYRK1A mutants. The 
cells were maintained at 37ºC in Dulbecco´s modified Eagle medium (DMEM; 
Invitrogen), with 10% fetal bovine serum (FBS; Invitrogen) and supplemented with 
antibiotics (100 µg/ml penicillin and 100 µg/ml streptomycin; Invitrogen). The cells 
were transfected by the calcium phosphate precipitation method and processed 48 h 
after transfection. 
 
2.4. In vitro kinase (IVK) assays 
Cells were washed in phosphate buffered saline (PBS) and then lysed in HEPES 
lysis buffer (50 mM Hepes [pH 7.4], 150 mM NaCl, 2 mM EDTA, 1% NP-40) 
supplemented with a protease inhibitor cocktail (#11836170001, Roche Life 
Science), 30 mM sodium pyrophosphate, 25 mM NaF and 2 mM sodium 
orthovanadate. The lysates were cleared by centrifugation and incubated overnight 
at 4ºC with protein G-conjugated magnetic beads (Dynabeads, Invitrogen) previously 
bound to an antibody against HA (Covance, #MMS-101R). The beads were then 
washed 3 times with HEPES lysis buffer and used for either IVK assays or to probe 
Western blots to control for the presence of HA-tagged DYRK1A. For the IVK 
assays, immunocomplexes were washed in kinase buffer (25 mM HEPES [pH 7.4], 5 
mM MgCl2, 5 mM MnCl2, 0.5 mM DTT) and further incubated for 20 min at 30ºC in 20 
µl of kinase buffer containing 50 µM ATP, [γ32P]-ATP (2.5x10-3 µCi/pmol) and with 
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200 µM DYRKtide as the substrate peptide. The incorporation of 32P was determined 
as described previously (Himpel et al., 2000), and the kinase activity was normalized 
to the amount of DYRK1A protein present in the immunocomplexes determined in 
Western blots (see Supplementary Materials and Methods for details and Table 3 for 
information on primary antibodies). DYRK1A autophosphorylation was analyzed by 
SDS-PAGE fractionation of the immunocomplexes and exposure of the dried gel to 
film. 
 
2.5. RNA extraction, microarray analysis and RT-qPCR 
Postnatal day (P) 0 and P7 mice were sacrificed by decapitation and the brain 
cortices were dissected out and stored at -80ºC. The tissue samples were 
homogenized in a Polytron and the total RNA was extracted with the TriPure 
Isolation Reagent (Roche). A RNA clean-up step was performed using the RNeasy 
Mini Kit (Qiagen) followed by DNAse I treatment (Ambion). Only RNA samples with 
an integrity number above 8.0 (Agilent 2001 Bioanalyzer) were used for further 
analysis. For microarray studies, the total RNA was hybridized to an Affymetrix 
Mouse GeneChip 430 2.0 Array. RNA was analyzed by reverse transcription coupled 
to quantitative PCR (the sequence of the qPCR primers is found in Supplementary 
Table 4) or using a low-density array (probes included in Supplementary Table 5). 
For more detailed information see Supplementary Materials and Methods. 
 
2.6. Video-EEG recordings 
Video-EEG recordings of adult Dyrk1a+/+ and Dyrk1a+/- male mice (8 animals each 
genotype) aged 5-6 months were obtained as described elsewhere (Garcia-Cabrero 
et al., 2012). Two home-made EEG stainless steel electrodes were implanted 
symmetrically into an anesthetized mouse over the cortex in front of bregma, and the 
ground and reference electrodes were placed posterior to lambda (Fig. 2C). A plastic 
pedestal (Plastic One Inc., Roanoke, VA, USA) was used to attach the pins of the 
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electrodes, and the headset was fixed to the skull and the wound closed with dental 
cement (Selectaplus CN, Dentsply DeTrey GmbH, Dreireich, Germany). Four days 
after surgery, synchronized video-EEG activity was recorded for 48 h in freely 
moving mice using a computer-based system (Natus Neurowork EEG, Natus Medical 
Inc., San Carlos, CA, USA). EEG seizure activity was examined by inspecting the 
entire EEG records and behavioral correlations were reviewed within the 
corresponding video-type segments. 
 
2.7. Behavioral Tests 
The social and stereotyped behaviors (social interaction and marble-burying tests) of 
adult 4-6 month old Dyrk1a+/+ and Dyrk1a+/- male mice (12-15 animals each 
genotype) were tested in a dedicated room for behavioral studies during the light 
phase. Before the experiment, the animals were habituated to the room for at least 
30 min and during the test, the mice were recorded from above with a video-camera 
CCTV (Sonny Corporation). The animal’s behavior was analyzed by an observer 
blind to their genotype using the SMART 3.0 software (Panlab Harvard Apparatus). 
 See Supplementary Materials and Methods for more details on these procedures as 
well as for the UsV analysis. 
 
2.8. Tissue preparation, immunostaining, and cell and synapse counts 
To obtain brain tissue, P7 and adult mice were deeply anesthetized and 
transcardially perfused with 4% paraformaldehyde. The mouse’s brain was removed 
and post-fixed, and cryotome or vibratome brain sections were immunostained as  
described previously (Barallobre et al., 2014). To quantify neurons and synapses, 
images were obtained on a Leica AF6500 motorized wide-field microscope and a 
Zeiss LSM780 confocal microscope, respectively. To quantify BrdU-labeled cells, 
images were obtained on an Olympus BX51 motorized microscope with a JVC digital 
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color camera. The procedures for immunostaining, and cell and synapse 
quantification are indicated in the Supplementary Materials and Methods. The source 
of the primary antibodies for these procedures is indicated in Supplementary Table 6. 
 
2.9. Statistical analysis 
Statistical analyses were performed with GraphPad Prism v5.0a (GraphPad 
Software) or with SPSS (IBM Analytics Software). The data from the IVK studies 
were analyzed with a 2-tailed unpaired Mann-Whitney test, synapse counts with a 
nested one-way ANOVA test, and the rest of the analysis was performed with a two-
tailed unpaired Student’s t-test. Differences were considered significant at p < 0.05. 
In the histograms, the data are represented as the mean ± standard error of the 
mean (SEM). 
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3. Results 
3.1. DYRK1A missense mutations in individuals with DYRK1A 
haploinsufficiency are loss-of-function mutations 
The kinase activity associated with most of DYRK1A missense mutations has been 
inferred from their position within the DYRK1A catalytic domain (Evers et al., 2017). 
Given that experimental data supporting the predicted models have been reported 
very recently for only a few DYRK1A missense mutations (Widowati et al., 2018), we 
set out to analyze the kinase activity of all missense mutations within the DYRK1A 
catalytic domain published to date and some others included in the ClinVar database 
(www.ncbi.nlm.nih.gov/clinvar/?term=DYRK1A[gene]). We also included 2 missense 
mutations in the non-catalytic C-terminal region (R528W and T588N) and 3 
mutations generating truncated proteins at the end of the kinase domain and 
predicted to contain the whole catalytic domain (Fig. 1A and Supplementary Table 1). 
These mutations were introduced into a DYRK1A expression plasmid and the 
catalytic activity of each of the mutants was evaluated using an IVK assay with the 
DYRKtide peptide as the substrate (see experimental design in Fig. 1B). The activity 
of most of the missense mutants was comparable to that of the DYRK1A K188R 
kinase-dead mutant (Fig. 1C), although the L295F, Q313H and R438H mutants 
rendered proteins with half the activity of the WT protein (Fig. 1C). However, some of 
the mutations did not alter the DYRK1A catalytic activity (K167R and T588N), and six 
even enhanced the enzyme’s kinase activity: A195T, H223R, L259F, R458M, G486D 
and R528W (Fig. 1C and Supplementary Fig. 1A). Notably, the activity of the 
truncated proteins increased with the length of the resulting protein, with truncations 
at R467 (before the α-helix I) devoid of activity, and at F478 (downstream α-helix I) 
with just 10% activity (Fig. 1C). Moreover, the fact that the A498Pfs93* mutant does 
not have similar catalytic activity to the WT protein might indicate that all or part of 
the non-catalytic C-terminal region is required for full DYRK1A kinase activity. Of 
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note, the crystal structures of DYRK1A have been obtained with truncated proteins 
that, based on our data, are not fully active (Soundararajan et al., 2013). 
 Considering the mode of activation of DYRK1A (Lochhead et al., 2005), the 
negative results in the IVK assays could be due to defective autophosphorylation of 
the Tyr residue in the activation loop, or to the inability of the mutants to 
phosphorylate an exogenous substrate. The lack of activity on the substrate was 
correlated with a lack of Tyr phosphorylation (Fig. 1D), suggesting that the mutations 
altered the activation of the kinase. We also evaluated the autophosphorylation of the 
mutant proteins (Fig. 1B), an activity associated with the mature kinase (Himpel et 
al., 2001), and only the catalytically active mutant enzymes were seen to 
autophosphorylate, with the exception of the truncated mutant A498Pfs93* (Fig. 1D 
and Supplementary Fig. 1B and C). In this latter case, either the autophosphorylation 
sites are located in the missing C-terminal region or the mutation alters the substrate 
preference of the protein. Together, these results indicate that most but not all of the 
missense DYRK1A mutants reported to date in DHS are bona-fide LoF mutants. 
 There is deficient accumulation of the kinase-dead DYRK1A K188R mutant 
(Kii et al., 2016) and therefore, we evaluated the quantitative expression of these 
mutants and their stability (Fig. 1E: stability index). We confirmed the reduced 
accumulation of the K188R mutant relative to the WT protein (Fig. 1F), and a similar 
behavior was observed for other catalytically inactive mutants (Fig. 1F and 
Supplementary Fig. 2). In fact, kinase activity and protein stability were positively 
correlated (Fig. 1G), suggesting that in heterozygosis, the proteins expressed from 
the mutant allele will not accumulate as much as the WT protein, thereby reducing 
their potential dominant-negative activity. 
 
3.2. Stereotyped behavior and epileptic activity of Dyrk1a+/- mice 
Seizures, stereotypies and social anxiety are frequent in DHS (Earl et al., 2017; van 
Bon et al., 2016). The Dyrk1a+/- mouse is more sensitive to the convulsive agent 
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pentylenetetrazol (Souchet et al., 2014) and it displays anxiety-like behavior in the 
open field (Fotaki et al., 2004), although ASD-like behaviors and epileptiform activity 
have not been reported in this model. Recently, a mouse carrying a frame-shift 
mutation in Dyrk1a has been generated and mice heterozygous for this mutation 
develop deficits in social contacts and communicative ultrasonic vocalization (UsV), 
as well as hyperthermia-induced seizures (Raveau et al., 2018). Dyrk1a+/- pups 
displayed similar deficits in UsV when separated from their mothers (Supplementary 
Fig. 3A). Moreover, adult Dyrk1a+/- mice engaged in shorter social olfactory 
interactions (oral-oral or oral-genital sniffing) in the resident-intruder test, while more 
time was spent on repetitive digging and self-grooming (Fig. 2A). Stereotyped 
behaviors were further evaluated in the marble-burying test, and the Dyrk1a+/- mutant 
mice buried fewer marbles and spent less time digging than their WT littermates (Fig. 
2B and Supplementary Fig. 3B). Furthermore, Dyrk1a+/- mutants spent less time 
exploring the central region of the cage where the marbles were buried (Dyrk1a+/+ 
288±41 s, Dyrk1a+/- 133±15 s; p <0.001, Student’s t-test). This time difference is 
unlikely to be caused by less locomotor activity, as both genotypes entered the 
central region a similar number of times (Dyrk1a+/+ 41±5, Dyrk1a+/- 35±4 s; p <0.314, 
Student’s t-test). Rather, Dyrk1a+/- mice spent significantly longer on repetitive self-
grooming (Fig. 2B). Together, these results show that in addition to deficits in social 
communication, haploinsufficient Dyrk1a+/- mice develop repetitive and stereotyped 
behaviors. 
The epileptic activity in Dyrk1a+/- mice was evaluated from video-EGG 
recordings (Fig. 2C-H), which revealed differences in the basal activity between the 
distinct genotypes (Dyrk1a+/+ 9-12 Hz; Dyrk1a+/- 6-7 Hz: Fig. 2D). Spontaneous 
myoclonic jerks that corresponded to interictal epileptiform activity were evident in 
Dyrk1a+/- mice, with isolated spikes, polyspikes and spike-wave discharges (Fig. 2E-
G). These mutant mice also experienced periods of immobility, during which 
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grooming, feeding and exploration were suppressed. Such periods of inactivity, 
alternating with shorter ones of epileptic activity, were characterized by groups of 
spikes and polyspikes in the EEG recordings (Fig. 2E and F). At times, the epileptic 
activity in Dyrk1a+/- mice coincided with situations of moderate handling stress. In half 
of the Dyrk1a+/- mice (4 out of 8), spontaneous generalized tonic-clonic seizures were 
recorded that lasted for different periods, with distinct lengths of tonic and clonic 
phases, and motor correlates that corresponded to stage 5-6 in the modified Racine 
Scale (Luttjohann et al., 2009; see Fig. 2H and Supplementary Movie). Notably, 
about half of the patients with mutations in DYRK1A develop epilepsy, displaying 
atonic attacks, absences and generalized myoclonic seizures (van Bon et al., 2016). 
Thus, epileptic activity seems to be a common characteristic in humans and mice 
with DHS. 
 
3.3. Alterations in neuron numbers in the developing neocortex of Dyrk1a+/- 
mice 
The neocortex is a six-layered structure essential for higher cognitive functions and 
sensory perception. Most neocortical neurons (more than 80% in the mouse) are 
projection excitatory neurons that extend their axons to intracortical or subcortical 
targets and use glutamate as neurotransmitter. The distinct types of excitatory 
neurons are produced in the embryo dorsal telencephalon (from E11.5 to E17.5 in 
the mouse) in overlapping temporal waves. The first neurons formed are those that 
are closest to the ventricle (layer VI neurons) and the last formed are those neurons 
located in the most superficial layers (layers II-III neurons) (Florio and Huttner, 2014; 
Molyneaux et al., 2007). We previously showed that production of the early-born 
cortical neurons is enhanced in Dyrk1a+/- embryos (Najas et al., 2015). To obtain 
further evidence as to how Dyrk1a haploinsufficiency affects corticogenesis, we 
counted the number of neurons that express the neuronal marker NeuN in the 
internal (V-VI) and external (II-IV) layers of the somatosensorial cortex (SSC) at P7 
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(Fig. 3A), when radial migration has ended and excitatory neurons adopt their final 
positions (Miller, 1995). The neocortical layers were thinner in postnatal Dyrk1a+/- 
mice, while they contained more neurons than their Dyrk1a+/+ littermates (Fig. 3B and 
C). The fact that the neuronal densities in the internal and external layers of Dyrk1a+/- 
mutants are similarly affected (Fig. 3C) suggests that Dyrk1a haploinsufficiency may 
alter neuron production along the neurogenic phase of cortical development. This 
possibility was evaluated with BrdU-birthdating analysis (Fig. 3D-F). The results 
showed that P7 Dyrk1a+/- animals had more BrdU+ cells in the SSC than WT animals 
when the BrdU labeling was performed at E13.5 (Fig. 3D), indicating that 
neurogenesis is enhanced in the Dyrk1a+/- mutant at this developmental stage. By 
contrast, Dyrk1a+/+ and Dyrk1a+/- animals displayed similar numbers of BrdU+ cells 
when the treatment was performed at E15.5 (Fig. 3F). Additional BrdU-labeling 
experiments indicated that cortical neurogenesis in Dyrk1a+/- embryos ends at the 
correct time (Supplementary Fig. 5). Consistent with the temporal generation of 
cortical excitatory neurons (Molyneaux et al., 2007), the BrdU-labeled cells 
generated at E15.5 were concentrated in the external layers of P7 WT animals, while 
the labeled cells generated at E13.5 showed a broader layer distribution, with BrdU+ 
cells located in both internal and external layers (Fig. 3E and G). Additionally, the 
distribution of BrdU-labeled cells in Dyrk1a+/- animals was similar to that in WT 
animals (Fig. 3E and G), indicating that radial migration of excitatory neurons is not 
affected in the Dyrk1a+/- model. Taking all the results together, we conclude that the 
augmented neuron density in the neocortex of Dyrk1a+/- mutants is the result of an 
increased neuron production during early and mid-corticogenesis. 
 Finally, the differentiation of excitatory neurons was assessed by studying the 
layer-specific markers Ctip2 (layer V) and Mef2c (layers II-IV). Dyrk1a+/- mutants 
have fewer Ctip2+ neurons and more Mef2c+ neurons than their WT littermates (Fig. 
3B and C). As the distinct types of neocortical excitatory neurons display different 
electrophysiological properties and project to distinct target areas (Molyneaux et al., 
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2007), the alteration in the proportions of these neurons could modify the final wiring 
of the brain in the Dyrk1a+/- mutants. 
 
3.4. Alterations to the synaptic circuitry in the neocortex of adult Dyrk1a+/- mice 
Around 10-15% of neocortical neurons are interneurons that make local connections 
and use γ-aminobutyric acid (GABA) as a neurotransmitter (Markram et al., 2004). 
These neurons maintain the stability of cortical networks and they modulate network 
activity through synaptic inhibition (Somogyi et al., 1998). In fact, disturbances to the 
excitation/inhibition ratio (E/I imbalance) in relevant brain circuits have been 
proposed as a common pathogenic mechanism in ASD (Rubenstein, 2010). 
 We have previously shown that the brain of adult Dyrk1a+/- mice present 
altered levels of proteins related to the glutamatergic and GABAergic systems 
(Souchet et al., 2014). Based on these data, we wondered whether the defects in 
cortical development displayed by the Dyrk1a+/- mice results in alterations in the adult 
circuitry. To this aim, we analyzed the excitatory (NeuN+/GABA-) and inhibitory 
(GABA+) neurons in the SSC of adult animals (Fig. 4A and B). The number of 
excitatory neurons in Dyrk1a+/- mutants increased in both the internal and external 
neocortical layers. The heterozygous mice also had more GABAergic neurons than 
their WT littermates, although the difference between these genotypes was only 
significant in the internal layers (Fig. 4B). The density of excitatory and inhibitory 
synapses was estimated in adult neocortices using antibodies against presynaptic 
markers VgluT1 (vesicular glutamate transporter 1) or VGAT (vesicular GABA 
transporter), and the postsynaptic markers Homer or Gephyrin. There was a 
significant increase in excitatory synapses in Dyrk1a+/- mutants in the two layers 
examined (IV and VI), while the density of inhibitory synapses in the mutant mice 
was similar to that in WT animals (Fig. 4C and D). The results suggest that the E/I 
imbalance in Dyrk1a+/- mice may provoke over-excitation in the cerebral cortex and 
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related brain areas, contributing to the epileptic activity and ASD-related behavior in 
these animals. 
 
3.5. Transcriptome alterations in the postnatal Dyrk1a+/- cerebral cortex 
The amount of Dyrk1a protein in the mouse developing neocortex increases during 
neurogenesis, reaching maximum levels in late embryonic development and during 
the first postnatal week (Dang et al., 2018). At these developmental stages, neural 
precursors shift their status and become gliogenic (Kriegstein and Alvarez-Buylla, 
2009), while neurons extend neurites and synaptogenesis begins (Li et al., 2010). 
These processes are coordinated by transcriptional programs that are dynamically 
regulated during development (Telley et al., 2016), and it is possible that alterations 
to these programs might contribute to the early neurological phenotype in Dyrk1a 
haploinsufficiency. To test this possibility, we compared the transcriptional profile of 
the cerebral cortex in Dyrk1a+/+ and Dyrk1a+/- mice at P0 and P7 (Supplementary Fig. 
7A for the microarray experimental design and Fig. 5A for the comparisons 
performed). The comparison of the Dyrk1a expression profile during cortical 
development in Dyrk1a+/+ and Dyrk1a+/- mice confirmed that Dyrk1a expression was 
reduced by half in the cortices of Dyrk1a+/- mice at any time-point, reflecting Dyrk1a 
haploinsufficiency (Supplementary Fig. 6). 
 The heatmap representation of the microarray expression data showed that 
the developmental effect on gene expression was more relevant than the effect of 
the reduction in Dyrk1a dose (Supplementary Fig. 7B).  In fact, the analysis of genes 
differentially expressed between P7 and P0 in Dyrk1a+/- cortex showed numbers 
similar to the WT samples (Fig. 5B; see also Supplementary Fig. 8 for validation of 
the microarray results and Supplementary Dataset 1). A large proportion of the 
genes that were differentially expressed during development in the WT samples 
changed in the same direction in Dyrk1a mutant samples (Supplementary Fig. 7B). 
However, the expression of many of the genes that were up-regulated during 
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development in the WT samples was diminished in Dyrk1a+/- samples and vice versa 
(Fig. 5C). These results suggest that Dyrk1a haploinsufficiency does not have a 
strong impact on the transcriptional program that drives postnatal cortical 
development but rather, that it might affect the time-course of the 
repression/activation of transcription. Nevertheless, the expression of a subset of 
genes was significantly altered between the two genotypes at P0 (182 genes) or P7 
(73 genes), with changes greater or less than 1.4 fold (Fig. 5D). 
 Pathway enrichment analysis of the genes differentially expressed when 
comparing P0 and P7 WT cortices showed that the up-regulated genes at P7 were 
associated with synaptic transmission, while the down-regulated ones were enriched 
in cell cycle-associated functions (Supplementary Fig. 9). These data are consistent 
with the developmental changes occurring in the neocortex, since differentiating 
neurons acquire terminal features. Indeed, at these stages most pluripotent 
progenitors in the ventricular zone lose their capacity to self-renew or become less 
proliferative, producing cells of the glial lineage (Kriegstein and Alvarez-Buylla, 
2009). When analyzing the genes with transcriptional changes in the Dyrk1a+/- 
samples compared to the WT ones, no particular enrichment was associated with the 
up-regulated genes in the Dyrk1a+/- animals, although known regulators of 
gliogenesis were identified in this set, such as Sox4 or Sox11 (Fig. 5E), suggesting a 
possible defect in the onset of glial cell production in the Dyrk1a+/- mutant model. By 
contrast, the down-regulated set was enriched in genes whose products are located 
in dendrites (Calb1, Penk, Thy1) and/or that are involved in axon growth (Nefl, Nefm) 
or synaptic transmission (Gabra, Gabrg1, Htr: Fig. 5E and Supplementary Dataset 
2). Hence, the transcriptional alterations detected further support that neuron activity 
is altered in the neocortex of Dyrk1a+/- mutant pups. 
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4. Discussion 
In this study, we analyzed a series of DYRK1A missense mutations, most of which 
are bona-fide LoF mutants that render the DYRK1A proteins enzymatically inactive. 
Moreover, the positive correlation between activity and protein accumulation might 
indicate that the presence of kinase-dead proteins has an added harmful effect. Very 
recently, the analysis of 5 DYRK1A missense mutants within the catalytic domain 
(L245R, D287V, L295F, F308V and S311F) has been published (Widowati et al., 
2018). Our results concur and further expand this analysis by including all missense 
mutations in the catalytic domain of DYRK1A published to date. Some of these 
mutations lie in regions predicted to be essential, as the case of K188 in the ATP-
binding domain or D287 and F308 (HCD- and DFG-motifs, respectively), which are 
involved in the catalytic reaction. There is a particular accumulation of LoF mutations 
within the P+1 loop and the α-helix F. In addition, though the number of missense 
mutations is still low, some residues can be considered as hot spots either because 
the mutation has been reported in two different patients (S346P: Bronicki et al., 2015; 
Deciphering Developmental Disorders, 2015; R467Q: (Evers et al., 2017; Posey et 
al., 2016)) and/or because the same residue is mutated to different amino acids 
(D287V and D287Y: Deciphering Developmental Disorders, 2015; Zhang et al., 
2015; S346P and S346F: Bronicki et al., 2015 and ClinVar SCV000712522). 
 Somewhat unexpectedly, the enzymatic activity of several missense mutants 
was indistinguishable from that of the WT kinase and in some cases, even an 
increment in activity was detected. We cannot exclude that the activity of some of 
these mutants could be the reflection of an altered substrate choice; alternatively, 
they might lead to other alterations in DYRK1A function affecting its final biological 
activity. A third possibility could be that they represent pathogenic variants of 
DYRK1A hyperactivity, based on the links of DYRK1A overexpression with certain 
DS pathological traits (Becker et al., 2014). Of note, the hyperactive G486D mutation 
was identified in a patient with macrocephaly (Dang et al., 2018), in contrast with the 
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DHS patients with LoF mutations in which microcephaly is, generally, observed 
(Supplementary Table 1). However, the results might also mean that these mutations 
do not provoke any negative effects. Indeed, the effects of the catalytic missense 
A195T and L259F mutants have been evaluated in cultured cortical neurons, where 
their impact on neurite extension was similar to that of the WT neurons (Dang et al., 
2018). Therefore, and for the catalytically active mutants, there is the possibility that 
the genetic variant in the DYRK1A gene is a benign variant and therefore not 
responsible for the clinical phenotype. 
 In ASD and ID syndromes, alterations to dendrite morphogenesis and 
synapse formation are common (de la Torre-Ubieta et al., 2016). There is evidence 
that DYRK1A regulates the actin cytoskeleton and microtubule dynamics, thereby 
contributing to the development and maintenance of neurites and dendritic spines 
(Martinez de Lagran et al., 2012; Ori-McKenney et al., 2016; Park et al., 2012). 
Indeed, the morphology of the dendritic arbor in neurons of the motor cortex is 
altered in Dyrk1a+/- mice and in transgenic mice overexpressing Dyrk1a (Benavides-
Piccione et al., 2005; Martinez de Lagran et al., 2012). These, together with the 
detrimental effect of DYRK1A truncated mutations in neuronal dendritic and spine 
growth (Dang et al., 2018) suggested that postnatal neocortical development is 
relevant to the neuropathology of DHS. However, our results indicate that Dyrk1a 
haploinsufficiency also affects neuron production in the developing neocortex leading 
to alterations to the number and proportion of the excitatory neuron subtypes. 
Considering that each of the many distinct excitatory neural subtypes fulfills a 
particular function (Jabaudon, 2017), subtle alterations in the proportion of these 
neurons would influence the activity of the synaptic circuits formed during postnatal 
development. In this context, the different transcriptomic profiles of the postnatal 
Dyrk1a+/- neocortex could be the consequence of its different neuronal composition. 
However, given that DYRK1A can directly or indirectly regulate transcription (Aranda 
et al., 2011; Di Vona et al., 2015), Dyrk1a haploinsufficiency might specifically modify 
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the transcriptional programmes in differentiating neocortical neurons. In any case, 
the transcriptome analysis highlighted the weaker expression of genes involved in 
neuritogenesis and synaptic activity in the postnatal Dyrk1a+/- neocortex. Therefore, 
both the reduction in gene expression and the direct activity of DYRK1A on proteins 
implicated on neuritogenesis should be considered as factors that contribute to the 
neurological alterations in Dyrk1a+/- mutant mice. 
 Adult Dyrk1a+/- mice experience epileptic activity and behavior deficits similar 
to those observed in other ASD mouse models in which excitatory and/or inhibitory 
synaptic circuits are perturbed (Lee et al., 2017). In fact, altered production and/or 
migration of excitatory and/or inhibitory cortical neurons affects the E/I balance in 
mature circuits, usually making them epileptogenic (Bozzi et al., 2012; Rubenstein, 
2010). Dyrk1a+/- mutants exhibit an excess of excitatory neurons and synapses in the 
neocortex, and these animals also show an excess of inhibitory neurons in the 
internal neocortical layers. Thus, we propose that both excitatory and inhibitory 
neurons contribute to the E/I imbalance underlying the epileptic activity, ASD-like 
behavior and cognitive deficits associated with DHS. 
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Figure Legends 
Fig. 1. DYRK1A missense mutations affect DYRK1A kinase activity, auto-
phosphorylation and protein stability. 
(A) Representation of the secondary protein structure of the DYRK1A catalytic 
domain, indicating the location of the mutants used in this study: AIK, HCD, DFG and 
YQY correspond to key functional elements	(Kannan and Neuwald, 2004). (B) 
Experimental procedure followed to analyze the parameters summarized in (C) and 
(D). (C) The graph represents the ability of the mutants to phosphorylate the 
DYRKtide peptide, with the WT kinase activity arbitrarily set as 100. The catalytically 
inactive mutant K188R was also included in the assay (n=3 independent 
experiments; ***p < 0.001, ns=not significant, unpaired 2-tailed Mann-Whitney's test). 
(D) Summary of the mutants' activity measured as the substrate phosphorylation, 
auto-phosphorylation and T-loop auto-phosphorylation (see Supplementary Fig. 1B 
and C). (E, F) Scheme of the assay used to assess the impact of the mutations on 
protein accumulation (E). A representative experiment is shown (F; see also 
Supplementary Fig. 2 for quantification). (G) Correlation analysis of the activity and 
stability of the DYRK1A mutants. The WT protein and the kinase-inactive K188R 
mutant are indicated as black and red dots, respectively (Pearson's correlation, r = 
0.9211; p < 0.0001). 
 
Fig. 2. Dyrk1a+/- mice display social deficits, repetitive behavior and epileptic activity. 
(A) Social interaction test. Time spent by adult mice on social interactions (sniffing) 
and repetitive behavior (digging and self-grooming). (B) Marble-burying test in which 
the number of buried marbles, and the time spent by adult mice digging and on self-
grooming was recorded over 20 min (n=12-15 mice each genotype: *p < 0.05, **p < 
0.01, ***p < 0.001, Student’s t-test). (C) Schematic drawing of a mouse skull 
indicating the electrode placement for EEG recordings. (D) Fragments of 
representative EEG recordings of the basal activity in Dyrk1a+/+ and Dyrk1a+/- mice. 
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(E-G) Representative EEG recordings of Dyrk1a+/- mice showing the spikes (E), 
polyspikes (F) and spike-wave discharges (G). (H) EEG recording of a spontaneous 
generalized tonic-clonic seizure lasting 74 s in a Dyrk1a+/- mouse (see also 
Supplementary Movie), with a 10 s amplified portion (black square) displaying spike-
wave activity at a frequency of 4-5 Hz. The arrow indicates the beginning of the 
clonic phase. 	
Fig. 3. Dyrk1a+/- mice show altered numbers of excitatory neurons in the postnatal 
neocortex. 
(A) Coronal brain section from a P7 Dyrk1a+/+ mouse stained with Hoechst indicating 
the position of the neocortical layers II to VI. Quantification in the somatosensorial 
cortex (SSC, white dashed rectangle). (B) Representative images of Dyrk1a+/+ (+/+) 
and Dyrk1a+/- (+/-) sections immunolabeled for NeuN, Mef2c or Citp2. (C) Histograms 
showing the thickness and number of neurons positive for the markers indicated in a 
350 µm wide column of the external (layers II-IV) and internal (layers V-VI) layers of 
the neocortex (n=4-5 animals each genotype). (D-G) Schedule of the BrdU-labeling 
protocol to estimate neuron production in E13.5 (D) and E15.5 (F) embryos and 
representative images of Dyrk1a+/+ sections immunolabeled for BrdU (brown signal) 
and the nuclei stained with Nissl. Histograms represent the total number of BrdU+ 
cells in Dyrk1a+/- animals relative to that in Dyrk1a+/+ animals arbitrarily set as 1 (D-
F), and the distribution of these cells in 10 equal bins, represented as the percentage 
of BrdU+ cells in each bin (E, G) (BrdU+ cells at E13.5, n=7-9 animals each genotype; 
BrdU+ cells at E15.5, n=5-6 animals each genotype). ns= not significant, *p < 0.05, ** 
p < 0.01, Student’s t-test. Bars = 100 µm (A) and 50 µm (B and D). 	
Fig. 4. Adult Dyrk1a+/- mice have a higher density of cortical neurons and synapses. 
(A) Representative images of the SSC from a Dyrk1a+/+ mouse section 
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immunolabeled for NeuN and GABA, and counterstained with Hoechst nuclear dye. 
(B) Images showing NeuN+ and GABA+ neurons in the SSC, and histograms with the 
quantification of NeuN+/GABA- (excitatory) and GABA+ (inhibitory) neurons in the 
external (layers II-IV) and internal (layers V-VI) layers of a 350 µm wide column of 
the SSC (n=4 animals each genotype; ns= not significant, *p < 0.05, **p < 0.01, 
Student’s t-test). (C, D) Representative confocal images of the SSC from a Dyrk1a+/+ 
mouse immunolabeled for VGluT1 and Homer (C), or for VGAT and Gephyrin (D), 
with the nuclei labeled with DAPI (blue). White rectangles indicate the area magnified 
in the images on the right. The white arrowheads point to interactions between 
presynaptic and postsynaptic markers. Box plots show the synapse densities 
between the first and third quartiles, the line in the boxes corresponding to the 
median synapse density (see Supplementary Fig. 4 for the automatic quantification 
of synapses). Excitatory synapses, layer IV (Dyrk1a+/+, n=639; Dyrk1a+/-, n=661) and 
layer VI (Dyrk1a+/+, n=639; Dyrk1a+/-, n=643). Inhibitory synapses, layer IV (Dyrk1a+/+, 
n=601; Dyrk1a+/-, n=539) and layer VI (Dyrk1a+/+, n=616; Dyrk1a+/-, n=535) (6 
animals per genotype; **p < 0.01, ns=not significant, nested one-way ANOVA). Bars 
= 200 µm (A), 10 µm (B), and 5 µm and 1 µm (left and right photographs respectively 
in C, D). 
 
Fig. 5. Transcriptome alterations in the neocortex of postnatal Dyrk1a+/- mice. 
(A) Schematic representation of the comparisons performed to identify differentially 
expressed genes during development or between genotypes. (B) Transcriptional 
changes in the P7 and P0 cortex from Dyrk1a+/+ or Dyrk1a+/- mice (adj. p ≤ 0.05; -1.4 
≤ FC ≥ 1.4). (C) Dot plots represent the changes in gene expression between 
genotypes (+/- vs +/+) at P0 and P7, and between the developmental stages (P7 vs 
P0) in the WT samples (+/+). Each dot represents a gene probe: green dots indicate 
probes with significant changes between genotypes (adjusted p-value <0.05); grey 
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dots genes with no significant change. The numbers in green correspond to the 
percentage of green dots in each quadrant. Light grey lines indicate the log2 fold-
change equal to ± 0.4. (D) The Venn diagrams show the genes up-regulated or 
down-regulated in comparisons of Dyrk1a+/- with Dyrk1a+/+ mice at the two 
developmental time points studied, with the overlap indicating genes altered at both 
P0 and P7 (adj. p ≤ 0.05; -1.4 ≤ FC ≥ 1.4). (E) Validation by RT-qPCR of selected 
genes with altered expression in Dyrk1a+/- animals. The graphs represent the mRNA 
expression relative to that in WT animals arbitrarily set as 1. RT-qPCR was used for 
Nfi1b, Penk, Htr7, Nefl and Nefm (n=4-9 animals each condition), and LDA for 
Gabrg1, Notch2, Sox4 and Sox11 (n=4 animals each condition; ns=not significant, *p 
< 0.05, Student’s t-test). 
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Abbreviations 
ASD, autism spectrum disorder; BrdU, bromodeoxyuridine; DHS, DYRK1A 
haploinsufficiency syndrome; DS, Down syndrome; DYRK, dual-specificity tyrosine-
regulated kinase; EEG, electroencephalogram; E/I, excitation/inhibition; GABA, γ-
aminobutyric acid; GFP, green fluorescent protein; ID, intellectual disability; IVK, in 
vitro kinase; LDA, low-density array; LoF, loss-of function; SSC, somatosensorial 
cortex; UsV, ultrasonic vocalization; WT, wild-type. 
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Supplementary Materials and Methods 
 
Western blots 
Samples were resolved by SDS-PAGE and the proteins were transferred onto 
nitrocellulose membranes (Amersham Protran). The membranes were blocked for 30 
min at room temperature with 10% skimmed milk (Sigma) diluted in 10 mM Tris-HCl 
[pH 7.5], 100 mM NaCl (TBS) plus 0.1% Tween-20 (TBS-T), and then incubated 
overnight at 4ºC with the primary antibodies (Supplementary Table 3) diluted in 5% 
skimmed milk in TBS-T. After several washes, the membranes were incubated for 45 
min at room temperature with horseradish peroxidase-conjugated secondary 
antibodies (DaKo) diluted in 5% skimmed milk in TBS-T. Antibody binding was 
detected by enhanced chemiluminiscence (Western Lightning Plus ECL, Perkin 
Elmer), which was analyzed on a LAS-3000 image analyzer (Fuji PhotoFilm). The 
antibody signal was quantified with the ImageQuant software. For relative protein 
accumulation, total cell extracts were used by resuspending the cell pellets in SDS 
loading buffer. For quantification, the signal of the HA-antibody was corrected with 
that of the GFP-antibody in co-transfections with pEGFP-C1 (Fig. 1E). 
 
Microarray experiments 
The experimental set up is depicted in Supplementary Fig. 6A. Total RNA was 
prepared from the cerebral cortex of P0 and P7 mice, obtained from two litters 
(Dyrk1a+/+, n=4; Dyrk1a+/-, n=4). Double stranded cDNA was synthesized from 100 
ng RNA using the Two Cycle cDNA Synthesis Kit (Affymetrix), according to the 
manufacturer’s instructions. After cRNA purification and fragmentation, the cRNA 
quality was checked (3'/5' ratio of probe sets <1.5, for Gapdh and Actb probes). The 
fragmented cRNA (15 µg) was added to the hybridization mix and used to fill the 
Affymetrix Mouse GeneChip 430 2.0 Array cartridge (over 39,000 mouse genes). 
The arrays were hybridized at 60ºC for 16 h with rotation in the Affymetrix GeneChip 
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Hyb Oven 640, washed and marked with streptavidin R-phycoerythrin following the 
Affymetrix protocol. After washing, the arrays were scanned in an Agilent G3000 
GeneArray Scanner and the images were processed with Microarray Analysis Suite 
5.0 (Affymetrix). Raw values obtained from the .CEL files were pre-processed using 
the Robust Multiarray Averaging Method (Irizarry et al., 2003), and the resulting 
normalized values were used for all subsequent analyses. The data were first 
subjected to non-specific filtering to remove low signal genes (those whose 
expression was below the third quartile of all expression values) and low variability 
genes (those whose standard deviation of the expression was below the third quartile 
of all standard deviations). All the statistical analyses were performed with the “R” 
statistical software and the libraries developed for microarray data analysis using the 
Bioconductor Project (www.bioconductor.org). Probes with an adjusted p-value ≤ 
0.05 that mapped to a known mouse gene were selected for the results shown in Fig. 
5 (Supplementary Dataset 1). 
 
RT-qPCR 
The cDNA was synthesized from 1 µg of total RNA using Superscript II 
retrotranscriptase (Invitrogen) and random hexamers. Real-time qPCR was carried 
out on the Lightcycler 480 platform (Roche), using the SYBR Green I Master kit 
(Roche) and cDNA diluted 1:10, mixing the reagents according to the manufacturer’s 
recommendations. In general, the PCR conditions were: one cycle 95°C 5 min; 45 
cycles 95°C 10 sec, 60°C 10 s and 72°C 10 s; one cycle 95°C 5 sec and 65°C 1 min. 
Primers for RT-qPCR, were designed using the “Primer3” tool (frodo.wi.mit.edu/cgi-
bin/primer3/primer3) to obtain 80-200 bp amplicons and optimal annealing 
temperatures between 59 and 61ºC for each primer pair (Supplementary Table 4). 
We used Ppia as a reference gene for data normalization. Each sample was assayed 
in triplicate and the Ct (threshold cycle) was calculated using the relative 
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quantification of the second derivative maximum method with the Lightcycler 480 1.2 
software (Roche). 
 For qPCR experiments on a Low Density array (LDA, Applied Biosystem), 
cDNA was synthesized from 0.5 µg of total RNA using MultiScribe retrotranscriptase 
and using random primers (High Capacity cDNA Reverse Transcription Kit, Applied 
Biosystem), according to the manufacturer’s recommendations. For quantitative 
analysis, the cDNAs were diluted 1:10 in H2O, added to TaqMan® Universal PCR 
Master Mix (Applied Biosystem) in a 1:1 ratio and loaded onto the LDA, pre-loaded 
with the selected TaqMan® Gene Expression Assays (Supplementary Table 5). The 
TaqMan Array was run on the 7900HT system (Applied Biosystem) following the 
manufacturer’s instructions, and the data were analyzed with the SDS software 
(Applied Biosystem), based on the Pfaffl Method (Pfaffl, 2001). We used Ppia and 
Actb as the reference genes for data normalization. 
 
Computational analysis 
The differentially expressed genes were selected based on a linear model analysis 
with empirical Bayes modification for the variance estimates (Smyth, 2004) and the 
p-values were adjusted using the Benjamini-Hochberg method (Benjamini and 
Hochberg, 1995). We used hierarchical clustering with Euclidean distances to form 
the groups of differentially expressed genes and the heat maps to visualize them. 
The annotation of the Affymetrix dataset was done with bioDBnet (biodbnet-
abcc.ncifcrf.gov; Mudunuri et al., 2009). The analysis of transcription factor and 
pathway enrichment was performed using the web server Enrichr 
(amp.pharm.mssm.edu/Enrichr; Kuleshov et al., 2016) and its associated 
visualization tools (Tan et al., 2013). The Ensemble (www.ensembl.org) and NCBI 
(www.ncbi.nlm.nih.gov) public databases were used to integrate the information 
regarding gene sequences and functions. 
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Behavioral Testing 
Social interactions 
Social interactions between two unfamiliar mice were evaluated using a modification 
of the reciprocal social interaction test (Lin and Hsueh, 2014). In brief, the subject 
animal was placed in a standard housed cage (12.5 cm x 17.5 cm x 32.5 cm) with 
clean bedding and after 5 min of habituation, a male of a different litter but on the 
same genetic background and age was introduced into the cage. The interactions 
between the two mice were videotaped during 5 min and the same intruder mouse 
was used in all tests. We scored the time spent in the social interactions (nose-to-
nose sniffing and nose-to-anus sniffing) that were initiated by the subject mouse and 
the time spent by this mouse performing stereotyped repetitive behaviors (digging 
and grooming). 
Marble-burying  
The marble-burying test was performed as described previously (Thomas et al., 
2009). In brief, mice were placed in a cage (17.5 cm x 24.5 cm x 42.5 cm) that had 
12 black glass marbles (15 mm diameter) evenly spaced in a 2 x 6 grid on top of 5 
cm of clean bedding. The mice were videotaped for 20 min, and we scored the 
number of marbles buried (90% or more covered) and the time spent by the mouse 
performing stereotyped repetitive behaviors (digging and grooming). 
Ultrasonic vocalization (UsV) 
UsV was measured in male and female pups at P3, P6, P9 and P12 (4 litters, 17-11 
animals each genotype). The dam was removed from a temperature-controlled home 
cage where the pups remained. The pups were then removed individually from the 
cage and transported in a dish into a hood equipped with a UsV recorder (Avisoft) 
where they were recorded for 5 min. Room temperature was maintained at 21ºC and 
the body temperature was measured with an axillary probe after the 5 min test. The 
data was analyzed with Avisoft SASLab Pro software. 
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Immunostaining 
To prepare cryotome sections, brains were cryoprotected with 30% sucrose in 
phosphate-buffered saline (PBS), while for vibratome sections brains were 
embedded in 4% agarose in H2O. For immunohistochemistry, cryotome sections (14 
µm) were collected on Starfrost precoated slides (Knittel Glasser) and distributed 
serially. For immunofluorescence, free-floating cryotome and vibratome sections (30-
45 µm) were distributed serially in 48-well plates. For bromodeoxyuridine (BrdU) 
antibodies the sections were treated for 30 min with 2N HCl at 37ºC before blocking 
(Najas et al., 2015). Immunohistochemistry was performed following the avidin-biotin-
peroxidase method (Vectastain ABC kit, Vector Labs, Burlingame, CA, USA) as 
described previously (Barallobre et al., 2014). In this case, samples were stained 
with Nissl (0.1% Cresyl violet acetate) to visualized non-immunopositive cells. For 
immunofluorescence, the sections were blocked for 1 h at room temperature in PBS 
containing 0.2% Triton-X100 and 10% fetal bovine serum (FBS), and probed for 18 
to 96 h at 4ºC with the primary antibodies (Supplementary Table 6) diluted in 
antibody buffer (PBS with 0.2% Triton-X100 and 5% FBS). For some antibodies, an 
antigen retrieval treatment was performed before blocking. The sections were then 
washed and the primary antibodies were detected using Alexa-555 or Alexa-488 
conjugated secondary antibodies (1:1000; Life Technologies). Cell nuclei were 
stained with Hoechst or 4′,6-diamidino-2-phenylindole,(DAPI; Sigma-Aldrich). For 
antibodies against Gephyrin and Homer, signal amplification was required and thus, 
after washing the sections they were incubated with the corresponding biotinylated 
secondary antibody (1:200; Vector Labs), and then with Alexa-488 conjugated 
streptavidin (Life Technologies). In all cases, the specificity of the immunoreaction 
was assessed by omitting the primary antibody. 
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Cell and synapse counts 
Wide-field and confocal microscope images were taken from the somatosensorial 
cortex (SSC) and processed using Image J/Fiji (Rasband, W.S., National Institutes of 
Health, Bethesda, Maryland, USA; imagej.nih.gov/ij). 
Cell counts 
Cells in postnatal animals were counted in 150 µm wide radial columns (NeuN+ 
cells), in 350 µm wide radial columns (Citp2+ cells and Mef2c+ cells) or in 500 µm 
wide radial columns (BrdU+ cells) of the SSC. Labeled cells in adult animals were 
counted in 150 µm wide radial columns (NeuN+/GABA- cells) or in 350 µm wide radial 
columns (GABA+ cells) of the SSC. All cell counts were obtained blind from images at 
the same rostro-caudal level of at least 3 sections per animal: from the beginning of 
the hippocampal commissure to the beginning of the hippocampus in P7 mice, and 
from bregma -0.22 to bregma -0.94 (Paxinos and Franklin, 2001) in adult mice. 
Synapse counts 
Tissue samples used for synapse counts where mounted in 2,2’-thiodiethanol 
adjusted to 1.51 refraction index in order to minimize chromatic shift. Synapses were 
counted in images from 3 sections at the same rostral-caudal level in each mouse 
(sections from bregma -0.22 to bregma -0.94). Twenty images (26 µm2) per 
hemisphere and layer were analyzed randomly from the SSC layers IV and VI on a 
Zeiss LSM780 confocal microscope equipped with a Plan Apochromat 63x oil 
(NA=1.4) objective. 2D confocal sections were acquired by sequential line scanning 
using the excitation lines 405, 488 and 561 and the respective detection bandwidths 
415-491, 490-553 and 568-735. The scanning speed was set at 3.15 µs/pixel and the 
resolution was adjusted to 50 nm/pixel. All images were acquired under the same 
parameters to guarantee the signals captured remained within the limits of the 
dynamic range of detection. A specific algorithm was developed in macro language 
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to automatically obtain the density of the synapses in all the images (see details in 
Supplementary Fig. 4).  
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Supplementary Table 1. Mutations analyzed in this study 
Mutation Codon changea Position
b Reference Clinical traits ClinVarh dbSNPi 
K167R AAA>AGA β-sheet 1 De Rubeis et al., 2014 No information - rs1456204748 
K188I AAA>ATA AXK-motif
c, 
β-sheet 3 Ji et al., 2015 
IUGR; seizures; microcephaly; short stature; ID; global DD; broad-based gait; 
minor skeletal abnormalities; severe speech delay; distinct facial gestalt SCV000206791 rs797044524 
A195T GCT>ACT α-helix C Dang et al., 2018 
global DD; problems in social interaction; anxiety; repetitive behaviors; mild ID with 
particular impairments in language; infantile spams; complex partial epilepsy with 
epileptic encephalopathy 
- - 
L207P CTT>CCT α-helix C, R-spined DDD et al., 2015 
IUGR; global DD; microcephaly; delayed speech and language development; cleft 
soft palate; abnormality of the skeletal system; abnormality of the palmar creases; 
amblyopia; astigmatism 
- - 
H223R CAT>CGT β-sheet 4 - No information SCV000620751 - 
L245R CTC>CGC α-helix D, C-spinee Ji et al,. 2015 
IUGR; global DD; ID; microcephaly; feeding difficulties in infancy; dysmorphic 
features; severe speech delay; brain abnormalities/MRI; skeletal anomalies; 
abnormal gait/ataxia; hand stereotypies; left renal agenesis 
SCV000206792 rs797044525 
L259F TTG>TTT α-helix E Dang et al., 2018 
ASD/ID/DD and pervasive developmental disorder, not otherwise specified: 
extremely low cognitive abilities and adaptive functioning, consistent with the mild 
range of ID; anxiety, perseveration and additional upsets and aggressive behavior 
- - 
A277P GCG>CCG α-helix E Evers et al., 2017 
global DD; postnatal microcephaly; decreased facial expression; hypoplastic left 
heart; micrognathia; retinal dystrophy SCV000571206 rs1064795422 
D287V GAT>GTT HCD-motif
f, 
R-spine DDD et al., 2015 
IUGR; microcephaly; feeding difficulties in infancy; early cataracts; short stature; 
specific learning disability; abnormality of the frontal hairline; single transverse 
palmar crease; cerebellar atrophy; ventriculomegaly; abnormality of the skin 
SCV000598121 - 
D287Y GAT>TAT HCD-motif, R-spine 
Zhang et al., 
2015 severe ID/DD; generalized tonic-clonic seizures, febrile seizures, status epilepticus - - 
L295F CTT>TTT β-sheet 7, C-spine Ji et al., 2015 
microcephaly; dysmorphic features; mild global DD; severe speech delay; skeletal 
anomalies; blepharophimosis; abnormal gait/ataxia 
SCV000206793 
SCV000321572 rs797044526 
F308V TTT>GTT DFG-motif
g, 
R-spine - No information SCV000247240 rs797045540 
S311F TCT>TTT β-sheet 9 Ruaud et al., 2015 ID; small stature; epilepsy; recurrent infections; microcephaly 
SCV000586742 
SCV000520979 rs1039571136 
Q313H CAG>CAT β-sheet 9 De Rubeis et al., 2014 No information - rs770863323 
R325H CGC>CAC P+1 loop - No information SCV000574147 rs1064796923 
Y327C TAT>TGT P+1 loop - No information SCV000599256 - 
R328W CGG>TGG P+1 loop Stessman et al., 2017 No information SCV000492371 rs113004433 
S346P TCC>CCC α-helix F DDD et al., 2015 seizures; global DD; microcephaly - rs724159951 
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S346P TCC>CCC α-helix F Bronicki et al., 2015 
seizures; feeding difficulties in infancy; deeply set eye; microcephaly; ID; absent or 
delayed speech development; hypermetropia/ myopia; large/dysplastic ears; thin 
upper lip; micrognathia; prone to infections 
SCV000196060 rs724159951 
S346F TCC>TTC α-helix F - No information SCV000712522 - 
L347R CTC>CGC α-helix F Trujillano et al., 2017 
microcephaly; ID; seizures; spasticity; global DD; motor delay; hypertonia; 
abnormal facial shape; cortical dysplasia; cortical gyral simplification; short stature - - 
R438H CGT>CAT CMGC-insert Wang et al., 2016 No information - rs1379071994 
R458M AGG>ATG α-helix H Dang et al., 2018 No information - - 
R467Q CGA>CAA N-terminal to 
α-helix I 
Posey et al., 
2016 
developmental regression; ID; hypotonia; mild ataxia; intention tremor; 
dysmorphisms; primary microcephaly; failure to thrive; demyelination; sun 
sensitivity; incontinence and anxiety 
SCV000245477 rs797045041 
R467Q CGA>CAA N-terminal to 
α-helix I 
Evers et al., 
2017 
micrognathia; low set ears; truncal obesity; facial asymmetry; lordotic posture with 
broad based gait; reduced muscle tone; feet brachydactyly with bilateral 
symmetrical 2-3 toe syndactyly; febrile convulsions in childhood- no seizures 
since; mild learning difficulties 
- rs797045041 
R467* CGA>TGA N-terminal to 
α-helix I Ji et al., 2015 
feeding difficulties in infancy; dysmorphic features; global DD; severe speech 
delay; moderate ID; seizures; brain abnormalities/MRI; skeletal anomalies; 
astigmatism 
SCV000206787 
SCV000245476 rs797044520 
F478Sfs1
12* 
AGT TTC 
>AGT TCT 
C-terminal to 
α-helix I 
Rump et al., 
2016 low birth weight; brachycephaly; hypertonia; severe DD - - 
G486D GGT>GAT C-terminal to 
α-helix I 
Dang et al., 
2018 ASD, learning disorder and macrocephaly SCV000747759 - 
A498Pfs9
3* 
CCC 
GCC>CCC 
GCA 
C-terminal to 
α-helix I 
O'Roak et al., 
2012 
microcephaly; global DD; speech delay; febrile and febrile seizures; recurrent otitis 
media with myringotomy; urinary problems; strep throat; head circumference of 48 
cm (z =-2.7) and normative BMI 
SCV000056592 
SCV000494645 rs1057519628 
R528W CGG>TGG non-catalytic C-end - No information SCV000594478 rs1448604709 
T588N ACC>AAC non-catalytic C-end 
Bronicki et al., 
2015 
seizures; feeding difficulties in infancy; deeply set eye; microcephaly; ID; absent or 
delayed speech development SCV000196065 rs724159955 
a, the nucleotide change is shown in bold; b, location of the amino acid change within the catalytic domain secondary structure; c, motif within the β3 strand in which the lysine couples the 
phosphates of ATP to the α-helix C (Taylor and Kornev, 2011); d, the R-spine or regulatory spine is a conserved spatial motif in active kinases (Kornev et al., 2006); e, the C-spine or 
catalytic spine is a conserved hydrophobic spine within the catalytic core (Kornev et al., 2008); f, key motif within the catalytic loop in which the central arginine has been replaced by a 
cysteine in the DYRK family of kinases alone (Kannan and Neuwald, 2004); g, motif where aspartic acid is critical for recognizing one of the ATP-bound Mg2+ ions (Taylor and Kornev, 
2011); h, ClinVar: www.ncbi.nlm.nih.gov/clinvar (Landrum et al., 2016); i, www.ncbi.nlm.nih.gov/variation/view. 
ASD, autism spectrum disorder; BMI, body mass index; DD, developmental delay; ID, intellectual disability; IUGR, intrauterine growth retardation; MRI, magnetic resonance imaging. 
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Supplementary Table 2. Primers used for site directed mutagenesis 
Name Sequence (5’ -> 3’)a 
K167R AATTGACTCCTTGATAGGCAGAGGTTCCTTTGGACAGGTTG 
K188I GCAAGAATGGGTTGCCATTATAATAATAAAGAACAAGAAGG 
A195T AAATAATAAAGAACAAGAAGACTTTTCTGAATCAAGCACAG 
L207P ACAGATAGAAGTGCGACTTCCTGAGCTCATGAACAAACATG 
H223R ATGAAATACTACATAGTGCGTTTGAAACGCCACTTTATG 
L245R GAAATGCTGTCCTACAACCGCTATGACTTGCTGAGAAAC 
L259F AATTTCCGAGGGGTCTCTTTTAACCTAACACGAAAGTTTGCGC 
A277P GCACTGCACTGCTTTTCCTTCCGACTCCAGAACTTAGTATC 
D287V ACTTAGTATCATTCACTGTGTTCTAAAACCTGAAAATATCC 
D287Y GAACTTAGTATCATTCACTGTTATCTAAAACCTGAAAATATCC 
L295F TAAAACCTGAAAATATCCTTTTTTGTAACCCCAAACGCAG 
F308V GTGCAATCAAGATAGTTGACGTTGGCAGTTCTTGTCAGTTGG 
S311F ATAGTTGACTTTGGCAGTTTTTGTCAGTTGGGGCAGAGG 
Q313H GACTTTGGCAGTTCTTGTCATTTGGGGCAGAGGATATACC 
R325H CTCTGGAGACCGATAAAAGTGACTCTGAATATACTGGTAb 
Y327C GTATATTCAGAGTCGCTTTTGTCGGTCTCCAGAGGTGCTAC 
R328W ATATTCAGAGTCGCTTTTATTGGTCTCCAGAGGTGCTACTG 
S346P CCTTGCCATTGATATGTGGCCCCTCGGGTGTATTTTGG 
S346F CCTTGCCATTGATATGTGGTTCCTCGGGTGTATTTTGG 
L347R TTTCAACCAAAATACACCCGCGGGACCACATATCAATGGCb 
R438H ATGACCTGACTCCCCAGCATGTCGCCCACCAGGTCCTCCb 
R458M TTCAAAGACCTCATTTTAATGATGCTTGATTATGACCCC 
R467* GATTATGACCCCAAAACTTGAATTCAACCTTATTATGC 
R467Q TGATTATGACCCCAAAACTCAAATTCAACCTTATTATGC 
F478Sfs112* TTATGCTCTGCAGCACAGTTCTTCAAGAAAACAGCTGATGc 
G486D CAAGAAAACAGCTGATGAAGATACAAATACAAGTAATAGTG 
A498Pfs93* TAGTGTATCTACAAGCCCCGCATGGAGCAGTCTCAGTCd 
R528W CAAGCAACAGTGGGAGAGCCTGGTCGGATCCGACGCACCAG 
T588N CATCCTGTTCAAGAAACAAACTTTCATGTAGCCCCTCAAC 
a, mutated codon is shown in bold; b, reverse complement; c, T deletion; d, C deletion. 
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Supplementary Table 3. Primary antibodies used for immunoblotting 
Antibody Host Source Dilution 
DYRK1A Mouse Abnova (H000001859) 1/1000 
DYRK1A Rabbit Abcam (ab69811) 1/1000 
GFP Mouse Clontech (632381) 1/2000 
HA Mouse Covance (MMS-101R) 1/2000 
phospho-Tyr (PY99) Mouse Santa Cruz (sc-7020) 1/1000 
α-Tubulin Mouse Sigma (T6199) 1/5000 
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Supplementary Table 4. Primers used for qPCR 
Gene symbol Sequence (5’ -> 3’; forward) Sequence (5’ -> 3’; reverse) 
Dyrk1a ATCCAGCAACTGCTCCTCTG CCGCTCCTTCTTATGACTGG 
Htr7 CCCTGAAACTTGCTGAGAGG CCAATGGTTTCGTTGTTTCC 
Nefl GAGCGAGATGGCCAGGTA TCTGAGAGTAGCCGCTGGTT 
Nefm ACAACCACGACCTCAGCAG TGGTATTCTCGCAAATGACG 
Nfi1b CGCATGGAGTCACTATTCCTG 
 
ATAAAATGGCTGGCTATGG 
 Penk AGCCAGGACTGCGCTAAAT GCAGGTCTCCCAGATTTTGA 
Ppia ATGGCAAGACCAGCAAGAAG TTACAGGACATTGCGAGCAG 
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Supplementary Table 5. Probes used in the Low Density Array  
Gene Symbol Assay ID Gene Symbol Assay ID 
Actb Mm00607939_s1 Nfib Mm00500784_m1 
Aplp2 Mm00507819_m1 Notch2 Mm00803077_m1 
Aqp4 Mm00802131_m1 Nrn1 Mm00467844_m1 
B3gnt1 Mm00723578_m1 Olfm3 Mm00462529_m1 
Chn1 Mm00472572_m1 Ppia Mm02342429_g1 
Cnp1 Mm00487038_m1 Ptger4 Mm00436053_m1 
Ddit4 Mm00512503_g1 Rab27b Mm00472653_m1 
Gabarapl1 Mm00457880_m1 S100b Mm00485897_m1 
Gabrb3 Mm00433473_m1 Slc32a1 Mm00494138_m1 
Gabrg1 Mm00439047_m1 Sox11 Mm03053654_s1 
Gfap Mm00546086_m1 Sox4 Mm00486320_s1 
Got1 Mm00494693_m1 Sst Mm00436671_m1 
Gpr6 Mm01701705_s1 Syt11 Mm00444517_m1 
Htr7 Mm00434133_m1 Thy1 Mm00493681_m1 
Itsn1 Mm00495015_m1 Tspan17 Mm00512218_m1 
Kifc2 Mm00495166_g1 Tspan2 Mm00510514_m1 
Lin7b Mm00457059_m1 Tuba4a Mm00849767_s1 
Mbp Mm01262035_m1 Unc13c Mm00463432_m1 
Myrip Mm00460563_m1 Vsnl1 Mm00449558_m1 
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Supplementary Table 6. Primary antibodies used for immunostaining 
Antibody Host Source Dilution 
BrdU Rat Serotec (OBT0030G) 1:100 
Ctip2* Rat Abcam (ab18465) 1:250 
GABA Rabbit Sigma-Aldrich (A2052) 1:200 
Gephyrin* Mouse Synaptic Systems (147 011) 1:500 
Homer* Mouse Thermo Scientific (MA1-045) 1:1000 
Mef2c* Rabbit Abcam (ab64644) 1:250 
NeuN Mouse Chemicon (MAB377) 1:1000 
VGAT* Rabbit Synaptic Systems (131 003) 1:400 
VGlut1* Guinea-pig Milipore (AB5905) 1:700 
*Citrate pretreatment 
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Supplementary Figure Legends 
 
Supplementary Fig. 1. Biochemical analysis of DYRK1A mutants. 
(A) Analysis of the DYRK1A mutants outside the catalytic domain, R528W and 
T588N. The graphs show the mean ± SEM, with the WT values set arbitrarily as 100 
(n=4, for DYRKtide phosphorylation; n=3, for autophosphorylation; n=3, for protein 
accumulation). (B) Analysis of the autophosphorylation activity of the DYRK1A 
mutants shown in Fig. 1. The graphs show the mean ± SEM, with the WT values set 
arbitrarily as 100 (n=3). In the authophosphorylation assays in A and B, nd refers to 
radioactive signals at the background level (ns= not significant, *p < 0.05, **p < 0.01, 
***p < 0.001, unpaired 2-tailed Mann-Whitney's test). (C) Representative images of 
the autophosphorylation assays for selected DYRK1A mutants. 
 
Supplementary Fig. 2. Protein accumulation analysis of DYRK1A mutants. 
Accumulation of DYRK1A mutants calculated as described in Fig. 1E, with the WT 
protein values set arbitrarily as 100 (mean ± SEM, n=3 independent experiments; 
ns= not significant, **p < 0.01, ***p < 0.001, unpaired 2-tailed Mann-Whitney's test). 
 
Supplementary Fig. 3. ASD-related phenotypes of Dyrk1a+/- mice. 
(A) Number and duration of UsV calls recorded over 5 min from pups when 
separated from their mothers at the developmental stage indicated (Dyrk1a+/+, n=17; 
Dyrk1a+/-, n=11). UsV data was analyzed by two-way ANOVA followed by a 
Bonferroni post-hoc test. The differences between the genotypes were statistically 
significant: F(1.94)=13.25, p = 0.0004 (number of calls) and F(1.92) =40.92, p < 0.0001 
(call duration), two-way ANOVA. Differences in call duration were significant in the 
Bonferroni post-hoc test (*p < 0.05, **p < 0.01). (B) Social contacts (sniffing) 
performed by Dyrk1a+/+ and Dyrk1a+/- mice in the social interaction test. The graph 
represents the number of sniffs (mean ± SEM) over 5 min distributed according to 
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their duration (X-axis correspond to seconds). Note that Dyrk1a+/- mice engaged in 
significantly fewer social contacts longer than 6 s: (n=12-15 mice each genotype; *p 
< 0.05, **p < 0.01, Student’s t-test). 
 
Supplementary Fig. 4. Scheme showing the workflow for the automatic 
quantification of synapses from confocal images using an image-processing 
algorithm written in Fiji macro language. 
(A) The macro opens a raw data image from a folder of choice (file with an extension 
*.lsm). (B) The algorithm splits the channels and normalizes their names to “Blue” 
(DAPI nuclear staining), “Green” (Alexa Fluor-488 for post-synaptic labeling of Homer 
or Gephyrin) and “Red” (Alexa Fluor-568 for pre-synaptic labeling of VgluT1 or 
VGAT). As Gephyrin (example in panel B) but not Homer is found in the nuclei, there 
were minor differences in the processing of the “Green” signal in some of the 
following steps. (C) The “Blue” channel is pre-processed to remove the noise by 
applying a Gaussian filter (Radius=2) and a Rolling Ball algorithm (Radius=80). An 
automatic threshold (Li) was then applied and the objects were filtered to generate a 
binary mask containing only the nuclei. In the case of Gephyrin+/VGAT+ images, the 
“Green” channel was pre-processed with a Gaussian filter (Radius=5), automatically 
thresholded (Huang) and the objects were filtered to generate a second mask 
containing only the nuclei. Both masks (Gephyrin and DAPI nuclear signals) were 
combined to obtain a single nuclear mask. (D) The inverted nuclear mask defines the 
working area, and this value was stored and used in the final calculation of synapse 
density, the selected area being used to estimate the median signal value of the 
“Red” channel. The median signal values for all the images in the data set were 
averaged to obtain a global median value, which was used at a later step as a 
reference to normalize the red channel. (E) To enhance spot discrimination, the 
original “Green” channel was filtered using the Laplacian of Gaussian (Radius=2) 
operator. After applying an automatic threshold (Otsu), the spots detected were 
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filtered according to size (0.01-100 µm2) and circularity criteria (0.6-1), and used to 
produce a binary mask. Finally, the watershed algorithm was used to further 
separate contiguous particles. (F) The segmented post-synaptic particles in the 
original “Green” channel were further filtered according to the density of their 
intensity, and small and/or weak particles below a certain threshold were 
discriminated. (G) To count synapses, the “Red” channel was first translated to 
correct for the chromatic shift (x=0.87 and y=1.31: values calculated using 
fluorescent microspheres), it was pre-processed with a Median filter (Radius=2) and 
Rolling ball algorithm (Radius=120) to remove noise, and it was normalized by the 
global median signal calculated in D. The macro counts a synapse as every green 
particle selected that overlies at least one pixel with a relevant intensity in the red 
channel. A verification image is then generated that contains all three processed 
channels and the synapse events highlighted in white. (H) The macro analyses all 
the images included in a folder of choice and delivers a text file for each image that 
contains the image name, the median red intensity value, the working area value, the 
number of segmented green particles, the number of filtered green particles and the 
number of synapses. Synapse density was calculated by dividing the number of 
synapses by the value of the working area. 
 
Supplementary Fig. 5. Neuron production in the dorsal telencephalon of E17.5 
Dyrk1a+/+ and Dyrk1a+/- embryos. 
(A) Schedule of the BrdU-labeling protocol to estimate neuron production in the 
developing neocortex. (B) Representative images of the SSC of P7 Dyrk1a+/+ and 
Dyrk1a+/- animals showing BrdU+ cells immunopositive for the neuronal marker NeuN 
(arrowheads). Bar = 50 µm. The histogram represents the number of BrdU+/NeuN+ 
neurons in a 500 µm wide column of the neocortex (n=3 animals each genotype; 
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ns=not significant, Student’s t-test). In both genotypes, the are few BrdU+/NeuN+ 
neurons and these neurons are positioned in the most external part of the neocortex.  
 
Supplementary Fig. 6. Dyrk1a expression in the developing cerebral cortex of 
Dyrk1a+/- mutants and their WT littermates. 
(A) Dyrk1a mRNA in the developing cerebral cortex of Dyrk1a+/+ and Dyrk1a+/- 
embryos or postnatal animals. The graph represents the mRNA expression relative 
to the levels in E11.5 Dyrk1a+/+ embryos set arbitrarily as 1 (n ≥ 3; **p < 0.01, 
Student's t-test, +/- vs +/+ at any time point). Note that the reduced Dyrk1a 
expression in the mutants is maintained during embryonic and postnatal 
development. (B, C) Representative Western blots of extracts prepared from P0 (B) 
and P7 (C) cerebral cortices and probed with the antibodies indicated. The 
secondary antibody was detected by infrared fluorescence using the LI-COR 
Odyssey IR Imaging System V3.0 (LI-COR Biosciences, Cambridge, UK). The 
graphs represent the Dyrk1a protein normalized to Vinculin levels and expressed 
relative to the WT animals. Note that there is approx. 50% less Dyrk1a in Dyrk1a+/- 
mice (n=3 mice each genotype): **p < 0.01, Student’s t-test. 
 
Supplementary Fig. 7. Gene expression in the postnatal Dyrk1a+/+ and Dyrk1a+/- 
cerebral cortex. 
(A) Experimental design indicating the animal number (#1 or #2), the genotype 
(Dyrk1a+/+, +/+; Dyrk1a+/-, +/-) and the litter (litters 2 and 3 for P0 samples and litters 
1 and 4 for P7 samples) used in the Affymetrix array. Experiment (Exp.) 1 and 2 
refers to the number of the array cartridge used for hybridization. Two samples for 
each experimental condition (developmental stage, genotype and litter) were 
included in each cartridge. (B) Heatmap showing gene expression in WT (+/+) and 
Dyrk1a mutant (+/-) samples at P0 and P7. The rows represent the individual probes 
and the values in the color-coded scale bar correspond to the standard deviation of 
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each probe from the log2 mean expression value. The differences between the 
genotypes are smaller than between the developmental stages and they were more 
evident at P0 than at P7. Note that inter- and intra-litter variability is similar. 
 
Supplementary Fig. 8. qPCR validation of the microarray data from a low-density 
array (LDA). 
Experimental details for the LDA are described in the Supplementary Materials and 
Methods, and the probes used are listed in Table 5. We selected a set of 36 genes 
that show the difference in expression between P7 and P0 in the WT (Dyrk1a+/+) 
samples on the Affymetrix array (adjusted p-value < 0.05). The qPCRs were 
performed in samples obtained from P0 and P7 Dyrk1a+/+ and Dyrk1a+/- animals (n=4 
animals of each genotype and developmental stage). The graphs represent the 
mean log2 fold-change in value of each gene obtained in the Affymetrix (black bars) 
and the LDA array (grey bars). Correlation of the log2 fold-change from the 
microarray and LDA results was calculated with a Pearson’s correlation test. The 
array and LDA results showed significant correlations in both Dyrk1a+/+ and Dyrk1a+/- 
samples. The changes in mRNA expression were consistent (up- or down-regulated 
at P7) through the two experimental approaches, with the exception of Aplp2 in the 
Dyrk1a+/+ samples and Ddit4 in the Dyrk1a+/- samples. The dotted lines indicate the 
log2 fold-changes equal to ±0.4. 
 
Supplementary Fig. 9. Pathway enrichment analysis of the transcriptome data in 
Dyrk1a+/+ cortices during development (P7 vs P0). 
Enrichment terms for the up-regulated and down-regulated genes at P7 relative to 
the P0 cortices of WT animals, determined using the Enrichr gene set enrichment 
analysis and visualization tools. The enriched terms are highlighted in color where 
the brightness indicates a lower p-value. Selective relevant enriched terms are listed 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/438861doi: bioRxiv preprint first posted online Oct. 10, 2018; 
	   25 
on the side on the canvas (ChEA, published ChIP-sequencing data sets; KEGG, 
cellular and molecular pathways database; MGI-MP, mammalian phenotypes from 
the Mouse Genome Informatics: see Supplementary Dataset 2 for a complete list of 
enriched terms). The CHEA analysis indicated that the up-regulated genes were 
enriched in Polycomb targets, whereas the down-regulated gene set was enriched in 
targets of the proliferation-associated transcription factor FOXM1. Note that the 
enrichment analysis of the mammalian phenotype ontology revealed terms like 
abnormal synaptic transmission, seizures and abnormal learning in the up-regulated 
gene set, and abnormal nervous system in the down-regulated set. 
 
Supplementary Movie. Example of a generalized tonic-clonic (GTC) seizure 
recorded in a Dyrk1a+/- mouse. The first manifestation of a GTC seizure is a typical 
Straub reaction, consisting of a rigid and erected tail lying across the back of the 
animal in an S-shaped curve. This reaction is followed by facial jerks, myoclonus, the 
mouse falling on its side and irregular twitches with hyperextension of the limbs, 
which evolves into a clonic stage with wild jumping and tonic hind-limb extension, 
and an after-seizure period of immobility. The onset of the GTC seizure is missed in 
the video-EEG because it occurred while connecting the mouse electrodes to the 
equipment after placing the mouse in the video-EEG cage. 
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